Tudor Investment Corp ET AL Purchases Shares of 37,943 Nurix Therapeutics, Inc. $NRIX

Tudor Investment Corp ET AL purchased a new position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) during the 3rd quarter, HoldingsChannel reports. The fund purchased 37,943 shares of the company’s stock, valued at approximately $351,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in NRIX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Nurix Therapeutics by 11.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,804 shares of the company’s stock worth $593,000 after buying an additional 5,286 shares in the last quarter. Millennium Management LLC raised its holdings in shares of Nurix Therapeutics by 106.2% in the 1st quarter. Millennium Management LLC now owns 874,399 shares of the company’s stock valued at $10,388,000 after acquiring an additional 450,262 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in shares of Nurix Therapeutics by 9.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 507,471 shares of the company’s stock valued at $6,029,000 after acquiring an additional 44,002 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Nurix Therapeutics by 8.7% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 159,530 shares of the company’s stock valued at $1,895,000 after acquiring an additional 12,817 shares during the last quarter. Finally, Creative Planning purchased a new position in shares of Nurix Therapeutics during the second quarter worth about $187,000.

Insider Buying and Selling at Nurix Therapeutics

In other Nurix Therapeutics news, CFO Houte Hans Van sold 3,661 shares of the business’s stock in a transaction on Friday, January 30th. The shares were sold at an average price of $16.60, for a total value of $60,772.60. Following the completion of the sale, the chief financial officer directly owned 45,427 shares of the company’s stock, valued at $754,088.20. The trade was a 7.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Gwenn Hansen sold 4,895 shares of the company’s stock in a transaction dated Friday, January 30th. The shares were sold at an average price of $16.60, for a total transaction of $81,257.00. Following the sale, the insider owned 83,672 shares of the company’s stock, valued at approximately $1,388,955.20. The trade was a 5.53% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 7.40% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on NRIX shares. HC Wainwright restated a “buy” rating and issued a $32.00 price objective on shares of Nurix Therapeutics in a research report on Tuesday, March 24th. Needham & Company LLC reiterated a “buy” rating and set a $26.00 target price on shares of Nurix Therapeutics in a research report on Thursday, January 29th. Stifel Nicolaus boosted their price target on shares of Nurix Therapeutics from $33.00 to $35.00 and gave the stock a “buy” rating in a research note on Thursday, January 29th. Weiss Ratings reissued a “sell (d-)” rating on shares of Nurix Therapeutics in a report on Thursday, January 22nd. Finally, Royal Bank Of Canada raised their price objective on shares of Nurix Therapeutics from $28.00 to $30.00 and gave the company an “outperform” rating in a research report on Thursday, January 29th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $30.54.

Nurix Therapeutics Price Performance

Shares of NRIX opened at $15.48 on Thursday. Nurix Therapeutics, Inc. has a 1 year low of $8.18 and a 1 year high of $22.50. The stock has a 50 day simple moving average of $16.03 and a two-hundred day simple moving average of $14.97. The firm has a market cap of $1.60 billion, a P/E ratio of -5.09 and a beta of 1.96.

Nurix Therapeutics (NASDAQ:NRIX) last announced its quarterly earnings data on Wednesday, January 28th. The company reported ($0.82) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.02. Nurix Therapeutics had a negative net margin of 314.90% and a negative return on equity of 57.51%. The firm had revenue of $13.58 million during the quarter, compared to analyst estimates of $13.41 million. On average, equities analysts anticipate that Nurix Therapeutics, Inc. will post -2.99 earnings per share for the current year.

About Nurix Therapeutics

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.